Incyte (INCY) Non Operating Investment Income (2015 - 2026)
Incyte's (INCY) quarterly Non Operating Investment Income came in at $9.8 million in Q2 2026, up 336.21% YoY from $2.2 million in Q2 2025, and up 48.76% on a QoQ basis from $6.6 million in Q1 2026.
Analysis
Incyte (INCY) Non Operating Investment Income (2015 - 2026) Analysis & Trends
Incyte (INCY) has 7 years of Non Operating Investment Income data on file, last reported at $9.8 million in Q2 2026.
- Quarterly Non Operating Investment Income rose 336.21% year-over-year to $9.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $43.2 million (up 250.75% YoY) and the FY2025 annual result came in at $21.3 million, down 81.63% from the prior year.
- Non Operating Investment Income improved to $9.8 million in Q2 2026, from $6.6 million in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $99.9 million in Q1 2024 to a low of -$26.7 million in Q3 2023.
- A 4-year average of $15.6 million and a median of $8.6 million in 2025 frame the typical range for Non Operating Investment Income.
- Annual changes were most pronounced in 2024 — Non Operating Investment Income tumbled 129.9% — and 2026, when it jumped 590.77%.
- Tracing INCY's Non Operating Investment Income over 4 years: stood at $34.1 million in 2023, then plunged by 129.9% to -$10.2 million in 2024, then surged by 279.22% to $18.2 million in 2025, then sank by 46.26% to $9.8 million in 2026.
- The last three Non Operating Investment Income figures came in at $9.8 million (Q2 2026), $6.6 million (Q1 2026), and $18.2 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | Incyte | 25.61 Bn | 21.07 Bn | 1.57 Bn | 9.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.81 Mn |
| Mar 31, 2026 | 6.59 Mn |
| Dec 31, 2025 | 18.25 Mn |
| Sep 30, 2025 | 8.56 Mn |
| Jun 30, 2025 | -4.15 Mn |
| Mar 31, 2025 | -1.34 Mn |
| Dec 31, 2024 | -10.18 Mn |
| Sep 30, 2024 | -12.98 Mn |
| Jun 30, 2024 | 39.24 Mn |
| Mar 31, 2024 | 99.95 Mn |
| Dec 31, 2023 | 34.05 Mn |
| Sep 30, 2023 | -26.65 Mn |
| Jun 30, 2023 | 41.81 Mn |
| Dec 31, 2017 | -21.93 Mn |
| Sep 30, 2017 | 23.05 Mn |
| Jun 30, 2017 | -19.57 Mn |
| Mar 31, 2017 | -5.81 Mn |
| Dec 31, 2016 | -23.76 Mn |
| Sep 30, 2016 | 24.30 Mn |
| Jun 30, 2016 | -854,000.00 |